A diagnosis involving both inflammation and the blood can mean seeing several specialists at once. A shared explanation—and a shared plan—can make that experience less confusing.
What is VEXAS?
VEXAS is an acquired condition linked to a change in the UBA1 gene in blood-forming cells. It usually begins in later adulthood and mainly affects men, although women can be affected. “Genetic” does not always mean inherited: VEXAS is generally not passed from a parent to a child.
The condition can involve inflammation together with abnormalities in blood counts or bone marrow. Possible features include fever, skin changes, cartilage inflammation, lung problems or blood clots. Many other illnesses can cause similar findings. Symptoms alone cannot establish the diagnosis.
How is it evaluated?
Diagnosis requires the appropriate molecular test interpreted with the clinical findings. Ask which sample and testing method were used and whether the report identifies a disease-causing UBA1 change. Bone-marrow findings may contribute to the assessment, but a single descriptive finding is not a substitute for the whole evaluation.
Keep copies of the actual genetic and hematology reports. They are easier to interpret than a summary saying only that a genetic test was positive.
Why more than one specialist?
Rheumatology and hematology often work together because inflammation and blood problems both need attention. Depending on the person, other specialists may also be involved. Ask who coordinates care and which team handles urgent questions, prescriptions and test results.
There is no single treatment plan for every person with VEXAS. Specialists consider the inflammatory illness, blood or marrow findings, treatment risks and the individual’s circumstances. Evidence is developing, and clinical trials may be part of the discussion.
Make your next appointment useful
- Bring a timeline of major episodes, hospital visits and treatment changes.
- Bring blood-count trends, relevant imaging and marrow reports, and the UBA1 report.
- List medicines, including glucocorticoid doses, and what happened when treatment changed.
- Ask what is being monitored and when the plan will be reviewed.
- Ask how infection concerns and new symptoms should be assessed.
The portable care summary can keep this information together. A caregiver or trusted supporter may help coordinate a complicated plan.
Do not assume every new symptom is VEXAS
New illness can have another cause, including infection or a treatment complication. Sudden breathing difficulty, severe chest pain, fainting, confusion or rapidly worsening illness needs urgent assessment. Follow the individual instructions from your treating team.
For clinicians: evaluating suspected VEXAS · Autoinflammatory disease in adulthood
Sources and further reading
General education, not a diagnosis or an individual treatment plan. Use these resources with your own care team. How this website is edited.